![]() |
|
By Peter Clark (Senior Editor, Autism Info Center) Wednesday 1st April 2026 |
The United States Food and Drug Administration has updated its position regarding the use of folinic acid for treating autism symptoms.
Recent political rhetoric had suggested that certain vitamin therapies could significantly improve the lives of autistic children or even prevent the condition entirely.
However, medical experts and regulators have now clarified that leucovorin is only approved for treating cerebral folate deficiency, which is a rare condition that may present with features similar to autism.
Scientific leaders express concern that misleading claims about simple cures can cause families to pursue unproven treatments without sufficient clinical evidence.
The retraction of a major study on the topic further highlights the necessity for rigorous scientific standards in the field of neurodevelopment.
Public health officials are being urged to rely on established research rather than speculative therapies to maintain public trust.
The debate underscores the ongoing challenges in providing accurate information to parents who are seeking support for their children in an environment often filled with misinformation.
Ensuring that medical interventions are safe and effective remains the primary goal for regulators overseeing developmental health.
It is essential to protect vulnerable families from dangerous or ineffective treatments while focusing on evidence-based support that truly benefits neurodivergent children across the nation.
Source: The Guardian (United Kingdom)
https://www.theguardian.com/us-news/2026/mar/22/
Copyright ©2026 Peter J. Clark T/A Autism Info Center / The Guardian (United Kingdom). All rights reserved worldwide. This information may not be copied, reproduced, excerpted, stored, indexed or distributed without the express written permission of the publisher, author, and copyright holder.